59 results about "Peptostreptococcus prevotii" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The invention relates to medicament combination preparation of medicinal compound taking cy-ethyl razepam medicinal compound containing cy-ethyl razepam or stereoisomer, pro-medicinal, medicinal salt, complex salt or / and salvation as effective constituent. The medicament combination preparation adopts the technical scheme that the cy-ethyl razepam medicinal compound, which has a general formula (1) structure and contains the cy-ethyl razepam or the stereoisomer, the pro-medicinal, the medicinal salt, the complex salt and the solvation, is taken as the effective constituent and forms the medicament combination preparation with a medicament carrier capable of being received on the pharmacy; and the preparation formulation is any preparation formulation said on the pharmacy. The invention also discloses an application of the medicament combination preparation in the process of treating the infection of bacteria taken as gram-positive bacteria like staphylococcus, pneumococcus, enterococcus faecalis, streptococcus, streptococcus bovis, streptococcus pneumoniae, peptostreptococcus, festering streptococcus pneumoniae, festering streptococcus pneumoniae, streptococcus pyogenes, streptococcus agalactiae, viridans streptococci, streptococcus bovis, streptococcus agalactiae B, group green streptococcus, corynebacterium diphtheriae and other bacteria.

The invention relates to a release injection which contains cefradine, wherein it is formed by release micro ball and dissolvent; the release micro ball contains release findings and penicillin antibiotic; the dissolvent is the special one contains sodium carboxymethyl cellulose as suspension agent; the viscosity is 100cp-3000cp (20Deg. C-30Deg. C); the release agent is selected from EVAc, polyphenyl, PLA, PLGA, sebacic acid polymer, protein pastern, and dope; the release micro ball can be made into release implant agent; the release implant agent and release injection is laid on bacteria stove or injected, to release the medicine for 5-30 days, to keep the effective medicine density and reduce the whole toxicity. The invention can be used to cure the infection caused by staphylococcus, streptococcus, etc.

The invention discloses a pharmaceutical composition and food for preventing or treating oral diseases. Both the composition and food comprise lactobacillus paracasei L9 and staphylococcus salivariusLD11. Studies show that the L9 and the LD11 can significantly alleviate the occurrence degree of E-level dental caries of an occlusal surface, after the composition and food containing the L9 and LD11are taken, the structures of oral floras change significantly, especially actinomycetes are significantly increased, and klebsiella, aerococcus, Gemella, corynebacterium and pseudomonas aeruginosa are significantly reduced in the category classification level. Taking of the L9 and LD11 can significantly reduce saliva species richness, the relative abundances of bacteria related to the oral diseases such as staphylococcus salivarius, actinomycetaceae and peptostreptococcus are significantly reduced, and periodontitis diseases may be alleviated; the species diversity of a dental plaque flora issignificantly reduced, the relative abundances of leptotrichia, fusobacterium and flavobacterium are all significantly reduced, and the oral diseases such as periodontal diseases, ozostomia and dental caries may be alleviated.

The invention relates to a release injection which contains mycin antibiotic, wherein the invention is formed by release micro ball and dissolvent; the release micro ball contains release findings and penicillin antibiotic; the dissolvent is the special one contains sodium carboxymethyl cellulose as suspension agent; the viscosity is 100cp-3000cp (20Deg. C-30Deg. C); the release agent is selected from EVAc, polyphenyl, PLA, PLGA, sebacic acid polymer, protein pastern, and dope; the release micro ball can be made into release implant agent; the release implant agent and release injection is laid on bacteria stove or injected, to release the medicine for 5-30 days, to keep the effective medicine density and reduce the whole toxicity. The invention can be used to cure the infection caused by staphylococcus, streptococcus, etc.

A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said domains being selected from the group consisting of domain 2, domain 3 and domain 4.

The invention belongs to the technical field of gene engineering and enzyme engineering, and discloses application of Peptostreptococcus asaccharoly glutamate dehydrogenase (GdhA) in increasing the yield of Bacillus licheniformis poly-gamma-glutamic acid. According to the invention, with a homologous recombination mode, glutamate dehydrogenase (GdhA) derived from Peptostreptococcus asaccharoly replaces glutamate dehydrogenase of Bacillus licheniformis (WX-02), the synthesis level of the Bacillus licheniformis poly-gamma-glutamic acid is remarkably improved, and the yield of the obtained strainpoly-gamma-glutamic acid is at least increased by 20% or above compared with that of a control strain. The invention provides a new strategy for efficient production of poly gamma-glutamic acid.

The invention discloses a preparation method and applications of gastric floating tablets containing ornidazole, belonging to a novel technical field of medicament and relating to a novel medicament form of ornidazole. 1. The gastric floating tablets are used to treat a plurality of diseases caused by bacteroides fragilis, bacteroides distasonis, bacteroides oval window, etc.; (2) oral cavity infections: pericoronitis, periapical periodontitis, pericoronitis, acute ulcerouse gingivitis etc.; (3) gynae infections: endometritis, myometritis, oviduct or ovarian abscess, pelvic cavity soft tissue infection, haemophilis vaginitis etc.; (4) surgical infections: wound infection, abscess of epidermis, bedsore ulcerouse infection, cellulites, gas gangrene etc.; (5) brain infections: meningitis, brain abscess; (6) septicaemia and severe general infections etc. 2. The gastric floating tablets are used to prevent infections before an operation and treat anaerobic infections after an operation. 3. The gastric floating tablets are used to treat urogenital canal trichomonas and giardia lamblia infections, such as trichomoniasis etc. 4. The gastric floating tablets are used to treat alimentary system amebiasis, such as amebic dysentery, amoebic liver abscess etc. The new medicament form is characterized in that the surface thereof is hydrated into gel after contacting with gastric juice at body temperature so as to cause volume expansion because the gastric floating tablets contain a plurality of hydrophilic macromolecule materials. Weight of the tablets is less than floating force of the gastric juice, so the tablets float on the gastric juice so as to prolong time in a stomach.

The invention provides a bacterium with an increased tolerance to butyric acids, such as 2-hydroxybutyric acid (2-HIBA). In particular, the invention provides a bacterium that tolerates at least 2.5 g / L of butyric acid. The bacterium may be derived, for example, from genus Clostridium, Moorella, Oxobacter, Peptostreptococcus, Acetobacterium, Eubacterium, or Butyribacterium.